Shares of Avadel Pharma climbed nearly 10% in morning trading Tuesday after the company announced it had received tentative approval for Lumryz, a formulation of sodium oxybate for the treatment of excessive daytime sleepiness.
https://www.pharmalive.com/wp-content/uploads/2022/07/sleepy-biospace-2022.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-07-20 09:30:082022-07-20 10:27:55Jazz’s toehold on sleep market slips with tentative Avadel FDA approval
